Advertisement
ANIX vs PRME
Which Stock Would AI Choose? Anixa Biosciences (ANIX) vs. Prime Medicine (PRME) Stock Comparison
Key Takeaways
- Different biotech niches: ANIX (Anixa Biosciences) focuses on cancer vaccines and CAR-T (chimeric antigen receptor T-cell) therapy, while PRME (Prime Medicine) is a gene-editing platform company built on "Prime Editing" technology.
- Scale and momentum differ: PRME has a meaningfully larger market capitalization and recently secured a high-value collaboration, while ANIX trades at a smaller valuation with early-stage clinical catalysts.
- Both remain pre-revenue and unprofitable: Neither company generates material product revenue, making clinical and regulatory milestones the primary drivers of share-price behavior.
- Analyst posture is constructive on both: Sell-side consensus reflects a "Buy" to "Strong Buy" tilt for each name, though target-price dispersion is wide given binary clinical risk.
- Risk profiles vary: PRME carries broader pipeline and partner validation but higher cash burn; ANIX offers a narrower, focused oncology pipeline with lower enterprise scale.
- For additional detail on each company's latest developments and daily trading action, explore the ANIX Major News and ANIX Today's Price Move pages, as well as the PRME Major News and PRME Today's Price Move pages.
- To see how automated systems are positioning across these and other tickers, explore Trending AI Robots.
Introduction
Anixa Biosciences (ANIX) and Prime Medicine (PRME) are both clinical-stage biotechnology companies, but they operate in different corners of the sector and attract different kinds of investors. ANIX is developing cancer vaccines and next-generation CAR-T therapies for ovarian and breast cancer, while PRME is pioneering Prime Editing, a platform approach to correcting genetic mutations underlying serious diseases. This stock comparison is relevant for traders and investors evaluating two pre-revenue biotech names whose fortunes hinge on clinical data, regulatory milestones, and partnership economics rather than current earnings. Understanding their relative performance, market positioning, and catalysts can help clarify where each fits within a risk-aware portfolio.
ANIX Overview and Recent Performance
ANIX, or Anixa Biosciences, is a San Jose, California-based biotechnology company focused on the treatment and prevention of cancer. Its pipeline centers on a breast cancer vaccine developed in partnership with the Cleveland Clinic and a CAR-T therapy for ovarian cancer conducted with Moffitt Cancer Center. The company is small by market-capitalization standards, reflecting its early stage and limited revenue base.
In recent weeks, ANIX has advanced its clinical programs through a series of incremental updates. The company administered a subsequent dose in its Phase 1 ovarian cancer CAR-T trial, submitted a protocol amendment for that study, and outlined a strategic plan for a Phase 2 breast cancer vaccine study. These developments have supported a generally constructive analyst view, with several firms maintaining Buy ratings and price targets well above the stock's recent trading range. That said, ANIX's shares have remained volatile and relatively range-bound over the trailing year, reflecting the binary nature of clinical-stage oncology assets and the absence of near-term revenue.
PRME Overview and Recent Performance
PRME, or Prime Medicine, is a Cambridge, Massachusetts-based biotechnology company developing one-time, curative genetic therapies using its proprietary Prime Editing platform. Its pipeline spans programs in blood and immune disorders, liver, lung, and other disease areas, including Wilson disease, alpha-1 antitrypsin deficiency (AATD), and chronic granulomatous disease (CGD).
Recent market activity has favored PRME, which advanced substantially in recent weeks on a combination of strategic and regulatory catalysts. The company announced a research collaboration and license agreement with Bristol Myers Squibb that included an upfront payment and milestone potential exceeding $3.5 billion, focused on ex vivo (outside-the-body) T-cell therapies. PRME also received U.S. FDA (Food and Drug Administration) clearance for its PM647 program in AATD, obtained Regenerative Medicine Advanced Therapy (RMAT) designation for its PM359 program, dosed the first patient in a Wilson disease study, and reported a favorable arbitration resolution with Beam Therapeutics. These events have strengthened sentiment, though the company's cash burn and pre-revenue status remain important considerations.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that trade thousands of different tickers across the market. Because only the most suitable strategies for current market conditions deserve a place in a curated list, Tickeron maintains a dedicated Trending AI Robots section. The bots featured there vary widely in trading style, strategy, timeframe, performance history, and the set of tickers they trade, ranging from short-term momentum approaches to longer-horizon trend-following systems. This diversity allows traders and investors to review quantitative, data-driven perspectives alongside traditional fundamental analysis. If you are interested in how automated models are currently positioning across names such as ANIX and PRME, visit the Trending AI Robots page to explore the available selection.
Head-to-Head Comparison
The clearest contrast between the two names is scope and stage of validation. PRME operates as a platform company with multiple programs and a marquee pharmaceutical partner, which broadens its potential catalyst calendar but also drives higher operating expenses and cash burn. ANIX, by contrast, is a focused, asset-driven developer with a smaller market capitalization and a more concentrated set of clinical readouts tied to its oncology programs.
On recent momentum, PRME has shown stronger relative performance, supported by partnership economics and a steady stream of regulatory and clinical milestones. ANIX's updates have been more incremental, and its shares have shown greater sideways volatility. From a risk standpoint, both companies face binary clinical outcomes, but PRME's larger enterprise scale and partner funding provide some cushion against dilution risk, while ANIX's smaller footprint means individual data points can move the stock more sharply in either direction. Sector exposure is similar—both sit in biotechnology—but their growth drivers differ: therapeutic validation for ANIX versus platform proof-of-concept and partnering for PRME.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst density, and relative positioning, Tickeron's AI would likely lean toward PRME in the current environment. The stock's stronger recent momentum, broader and better-funded pipeline, and partnership validation create a more consistent positive narrative than ANIX's narrower, event-driven catalyst set. That said, this is a probabilistic assessment rather than a definitive call: both names carry meaningful clinical risk, and ANIX's smaller size could produce sharper upside on positive oncology data. The AI's preference reflects relative trend and stability characteristics at this moment, not a forecast of guaranteed outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIX is a Hold and PRME is a Hold.
ANIX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ANIX moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ANIX moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 21 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 53 cases where ANIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ANIX broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on ANIX as a result. In 79 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ANIX just turned positive on October 22, 2026. Looking at past instances where ANIX's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
ANIX moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ANIX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +9.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIX advanced for three days, in 180 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. ANIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.627) is normal, around the industry mean (3.498). P/E Ratio (-9.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (384.615) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PRME's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for PRME moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 instances where the indicator moved out of the overbought zone. In 17 of the 17 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 40 cases where PRME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PRME turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 33 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
PRME broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PRME as a result. In 56 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
PRME moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PRME crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
The 50-day moving average for PRME moved above the 200-day moving average on October 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +11.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in 159 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 98 of 114 cases where PRME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.422) is normal, around the industry mean (3.498). P/E Ratio (-4.429) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PRME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ANIX | PRME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 95 | |
PRICE GROWTH RATING 1..100 | 55 | 36 | |
P/E GROWTH RATING 1..100 | 29 | 91 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRME's Valuation (27) in the null industry is somewhat better than the same rating for ANIX (68) in the Computer Peripherals industry. This means that PRME’s stock grew somewhat faster than ANIX’s over the last 12 months.
PRME's Profit vs Risk Rating (100) in the null industry is in the same range as ANIX (100) in the Computer Peripherals industry. This means that PRME’s stock grew similarly to ANIX’s over the last 12 months.
PRME's SMR Rating (95) in the null industry is in the same range as ANIX (98) in the Computer Peripherals industry. This means that PRME’s stock grew similarly to ANIX’s over the last 12 months.
PRME's Price Growth Rating (36) in the null industry is in the same range as ANIX (55) in the Computer Peripherals industry. This means that PRME’s stock grew similarly to ANIX’s over the last 12 months.
ANIX's P/E Growth Rating (29) in the Computer Peripherals industry is somewhat better than the same rating for PRME (91) in the null industry. This means that ANIX’s stock grew somewhat faster than PRME’s over the last 12 months.
| ANIX | PRME | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 77% | 1 day ago 88% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 79% |
| Advances ODDS (%) | 6 days ago 81% | 6 days ago 82% |
| Declines ODDS (%) | 8 days ago 82% | 8 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Aroon ODDS (%) | N/A | 1 day ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANIX’s FA Score shows that 1 FA rating(s) are green while PRME’s FA Score has 1 green FA rating(s).
- ANIX’s FA Score: 1 green, 4 red.
- PRME’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANIX’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).
- ANIX’s TA Score: 5 bullish, 5 bearish.
- PRME’s TA Score: 6 bullish, 5 bearish.
Price Growth
ANIX (@Biotechnology) experienced а +1.76% price change this week, while PRME (@Biotechnology) price change was -3.15% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
ANIX is expected to report earnings on Jan 06, 2027.
Industries' Descriptions
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ANIX and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANIX has been loosely correlated with PRME. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIX jumps, then PRME could also see price increases.
| Ticker / NAME | Correlation To ANIX | 1D Price Change % | ||
|---|---|---|---|---|
| ANIX | 100% | -0.47% | ||
| PRME - ANIX | 45% Loosely correlated | -7.53% | ||
| TNYA - ANIX | 42% Loosely correlated | +9.38% | ||
| RXRX - ANIX | 42% Loosely correlated | +8.10% | ||
| RCKT - ANIX | 41% Loosely correlated | +6.08% | ||
| CRSP - ANIX | 40% Loosely correlated | -0.06% | ||
More | ||||